hSmad (mothers against decapentaplegic)-related proteins are important messengers within the Transforming Growth Factor-b 1 (TGF-b 1 ) superfamily signal transduction pathways. To further characterize a member of this family, we obtained a full length cDNA of the human hSmad5 (hSmad5) gene by rapid ampli®cation of cDNA ends (RACE) and then determined the genomic structure of the gene. There are eight exons and two alternative transcripts; the shorter transcript lacks exon 2. We identi®ed the hSmad5 promoter region from a human genomic YAC clone by obtaining the nucleotide sequence extending 1235 base pairs upstream of the 5' end of the cDNA. We found a CpG island consistent with a promoter region, and we demonstrated promoter activity in a 1232 bp fragment located upstream of the transcription initiation site. To investigate the frequency of somatic hSmad5 mutations in human cancers, we designed intron-based primers to examine coding regions by polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis. Neither homozygous deletions or point mutations were found in 40 primary gastric tumors and 51 cell lines derived from diverse types of human cancer including 20 cell lines resistant to the growth inhibitory eects of TGF-b 1 . These results suggest that the hSmad5 gene is not commonly mutated and that other genetic alterations mediate the loss of TGF-b 1 responsiveness in human cancers.
hSmad (mothers against decapentaplegic)-related proteins are important messengers within the Transforming Growth Factor-b 1 (TGF-b 1 ) superfamily signal transduction pathways. To further characterize a member of this family, we obtained a full length cDNA of the human hSmad5 (hSmad5) gene by rapid ampli®cation of cDNA ends (RACE) and then determined the genomic structure of the gene. There are eight exons and two alternative transcripts; the shorter transcript lacks exon 2. We identi®ed the hSmad5 promoter region from a human genomic YAC clone by obtaining the nucleotide sequence extending 1235 base pairs upstream of the 5' end of the cDNA. We found a CpG island consistent with a promoter region, and we demonstrated promoter activity in a 1232 bp fragment located upstream of the transcription initiation site. To investigate the frequency of somatic hSmad5 mutations in human cancers, we designed intron-based primers to examine coding regions by polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis. Neither homozygous deletions or point mutations were found in 40 primary gastric tumors and 51 cell lines derived from diverse types of human cancer including 20 cell lines resistant to the growth inhibitory eects of TGF-b 1 . These results suggest that the hSmad5 gene is not commonly mutated and that other genetic alterations mediate the loss of TGF-b 1 responsiveness in human cancers.
Keywords: transforming growth factor-b; cDNA; genomic structure; PCR-SSCP The TGF-b 1 superfamily is a group of cytokines which regulate cell proliferation and dierentiation in a wide variety of organisms (Massague, 1996) . This family has more than 25 related proteins including the bone morphogenetic proteins (BMPs), activin, inhibin, Decapentaplegic (DPP), Vg1 and TGF-bs. These proteins have diverse functions including tissue dierentiation, suppressing epithelial cell proliferation, promoting wound repair, and regulating immune and endocrine functions (Massague, 1996) . Detailed signal transduction pathways are not described for most of these proteins, though signi®cant progress has been made recently for the TGF-b 1 pathway. It has been known for some years that TGF-b 1 initiates its signal by binding two transmembrane serine/threonine kinases called the type I and type II TGF-b 1 receptors (Lin et al., 1992; Franzen et al., 1993; Wrana et al., 1994) , but subsequent downstream signaling events were unknown. Recently, the Mad (mothers against decapentaplegic) gene in Drosophila and the Sma genes in Caenorhabditis elegans were linked to a signaling cascade from the TGF-b 1 type I and type II receptors (Sekelsky et al., 1995; Savage et al., 1996; . Related genes have been identi®ed in vertebrates Hahn et al., 1996; Riggins et al., 1996; Liu et al., 1996; Zhang et al., 1996; Eppert et al., 1996; Hayashi et al., 1997) including seven family members in the human, mouse and rat: hSmad1 (JV4-1) Riggins et al., 1996; Liu et al., 1996) , hSmad2 (JV18-1) (Riggins et al., 1996; Zhang et al., 1996; Eppert et al., 1996) , hSmad3 (JV15-2) (Riggins et al., 1996; Zhang et al., 1996) , hSmad4 (DPC4) (Hahn et al., 1996) , hSmad5 (JV5-1) (Riggins et al., 1996) , hSmad6 (Riggins et al., 1996) and hSmad7 (Hayashi et al., 1997) .
hSmad1 protein has been shown to accumulate in the nucleus after phosphorylation by BMP2 and BMP4 (Liu et al., 1996) . hSmad2 (Eppert et al., 1996) and hSmad3 proteins are phosphorylated and translocated in response to TGF-b 1 . hSmad2 is mutated in a fraction of colon cancers (Riggins et al., 1996; Eppert et al., 1996) , and it is implicated as an eector of activine as well as TGF-b 1 . hSmad4 (DPC4, i.e., Deleted in Pancreatic Cancer-4) was initially identi®ed as a candidate tumor suppressor gene in pancreatic cancer based on its chromosomal location at 18q21 which is commonly deleted in those tumors (Hahn et al., 1996) ; it also forms heterodimers with other hSmad proteins (Lagna et al., 1996; Zhang et al., 1996) . hSmad5 is located at chromosome 5q31 which is frequently deleted in human tumors (Riggins et al., 1996; Tamura et al., 1996) ; functional studies in a murine system show that hSmad5 protein is phosphorylated in a time-and dose-dependent manner in response to TGF-b 1 and causes growth arrest when overexpressed (Yingling et al., 1996) .
We determined the full length cDNA sequence for hSmad5, its genomic structure, and we characterized the promoter region. To facilitate genomic analysis of human tumors, we designed intron primers suitable for PCR-SSCP analysis of the complete coding region. Finally, we performed an initial mutation survey of 40 primary gastric tumors, which have common deletions at chromosome 5q31, and 51 human tumor cell lines, including 20 which are known to be resistant to the growth inhibitory eects of TGF-b 1 .
cDNA clone 214636 was reported to be a member of the human hSmad gene family and named JV5-1 (Riggins et al., 1996) . Based on the partial sequence of cDNA clone 214636, another EST cDNA (291982) containing the same sequence was found in the EST database. The EST cDNA clones, 214636 and 291982, were sequenced using the`long distance sequencer' method (Hagiwara and Gemma et al., 1997) and carry homology to the 3' region of other human mad-related genes: hSmad1, hSmad2, hSmad3, and hSmad4. Since 291982 was the longer of the cDNA clones, two rounds of RACE were performed using two exon-speci®c primer pairs to determine the 5' end of the cDNA sequence; two dierent cDNA sequences were obtained. The longer product, hSmad5 cDNA-1, contains an untranslated region of 357 bp at the 5' end, a methionine start codon, and an open reading frame Figure 1 hSmad5 produces two alternatively spliced cDNAs. The EST cDNA database was screened for the hSmad5 sequence using the BLAST program from the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov). Two cDNA clones, 214636 and 291982, were identi®ed and obtained from Genome Systems Inc. (St Louis, MO). The cDNA was extended in the 5' direction by PCR ampli®cation using reverse-transcribed human placental mRNA (CLONTECH Laboratories Inc. Palo Alto, CA) using two oligonucleotide primers derived from the longer cDNA clone, 291982: 5' ± 3'; GGATAAGGGCTGTTTGGAG and 5' ± 3'; GGAGATAAGGGAAAAGGAGTG. The PCR ampli®cation was performed using the 5'RACE System for Rapid Amplification of cDNA Ends, Version 2.0 kit (GIBCO BRL/LIFE TECHNOLOGIES, Gaithersburg, MD). Two new primers from the sequences obtained in ®rst RACE: 5' ± 3'; CGGA-GACCTTCCTGTAACTC and 5' ± 3'; CAGTGGCTACCGAAA-GAAC, were used to accomplish the second RACE. Two dierent cDNAs were obtained. (a) cDNA-1 is the longer Figure 2 shows predicted amino acid sequences aligned with other hSmad proteins. A second, shorter cDNA (hSmad5 cDNA-2) was identical to cDNA-1 except for the omission of 75 nucleotides in exon 2 (Figure 1 ). We collected 16 clones with cDNA-1 and 9 clones with cDNA-2 in the second RACE. The transcript (cDNA-1) was obtained using RT-PCR of human placental mRNA (CLONTECH Laboratories Inc., Palo Alto, CA) and cDNA-speci®c primer pairs: 5' ± 3'; CGCGAAAAGGAAGCTGTTGAAG (sense) and 5' ± 3'; GGAGATAAGGGAAAAG GAGTG (antisense). The Gene Amp XL RNA PCR kit (Perkin Elmer/Roche, Branchburg, NJ) was used for RT-PCR.
Primer extension analysis was used to identify the correct 5' end of the hSmad5 mRNA. This analysis revealed two major initiation sites near the 5' end of the cDNA obtained by the second RACE, indicating that this is the ®rst exon in the hSmad5 gene (Figure 3) . The 5' end of the hSmad5 mRNA sequence was deposited with the EMBL/GenBank Data Libraries under Accession Number AF009745.
We determined the genomic structure of hSmad5 by comparing the cDNA sequence to the genomic sequence obtained from human mega-YAC (yeast arti®cial chromosome, Research Genetics, Inc., Huntsville, AL), 759d5 and 745f8, which span the hSmad5 gene . This gene has eight exons, and the exon-intron boundaries are shown in Table 2 . The ORF comprises exons 3 through 8 ( Figure 1 , Table 2 ); exon 2 was deleted from the mRNA presumably by alternative splicing. Each exon sequence was deposited with the EMBL/GenBank Data Libraries under Accession Numbers AF009737-AF009744.
The promoter region of hSmad5 was cloned and characterized. A 40 base oligonucleotide corresponding to the region near the 5' end of the hSmad5 cDNA was used to screen the genomic sublibrary. Four clones containing the 5' end of the cDNA were identi®ed, and all contained identical sequences. Sequence analysis of the cDNA clones and YAC clone, 745f8, revealed 1235 nucleotides upstream of exon 1 (Figure 4a , Accession No. AF009736). This segment contained two GC-rich regions located at the¯anking region and about 1000 bp upstream from exon 1 (Figure 4b ). The Obs/ Exp ratio for CpG is greater than 0.6 in the segment extending 200 bp upstream from the transcription Figure 3 Primer extention analysis using 5' end-labeled primer from exon 1. A 32 P-labeled 23 base oligonucleotide (5' ± 3': CCTCGCTGCAACTTTATTAGCAG) was hybridized to human placental mRNA (CLONTECH Laboratories Inc., Palo Alto, CA) and subjected to primer extension with 200 U Moloney-Murine Leukemia Virus reverse transcriptase (CLON-TECH Laboratories Inc., Palo Alto, CA). Extension products were separated on a 6% polyacrylamide sequencing gel in parallel with a sequencing reaction by using the same primer on genomic DNA of hSmad5 subcloned into M13mp19. Sequence analysis was accomplished using the same primer hSmad5 cDNA, genomic structure, promoter and mutation analysis A Gemma et al starting site (Figure 4c ). This analysis showed that the promoter region of hSmad5 has a CpG island which starts 200 bp upstream of exon 1. This CpG island does not contain GC boxes (GGGCGG) that are potential Sp1 binding sites, and the promoter region lacks both TATA and CAAT boxes. Luciferase plasmids containing the hSmad5 promoter were generated by cloning PCR product into MluI and BglII sites of pGL3-Basic Vector (Promega, Madison, WI). The 5' primer contained the MluI site (5' ± 3': AGAACGCGTTTCCCCTTCACTCCTTTAC-TAGGC) and the 3' primer included the BglII site (5' ± 3': AGAAGATCTCCTCGCTGCAACTTTATTAG-CAG). Plasmids with or without the hSmad5 promoter region were transfected into COS-1 cells using LIPOFECTACE reagent (GIBCO BRL/LIFE TECHNOLOGIES, Gaithersburg, MD). The ratio of DNA/LIPOFECTACE reagent was 1 : 3 (mg/mg). Transfections were performed in triplicate. Forty-eight hours after transfection, protein extracts were prepared and luciferase activity was measured by Luciferase Assay Systems (Promega, Madison, WI). The cells transfected by the vector without the promoter region had 2400+1400 luminescence units/mg and those with the promoter region had 129 000+20 000 luminescence units/mg in luciferase activity. These data clearly demonstrated promoter activity within the examined sequence.
Using intron sequences¯anking the hSmad5 exons, we designed six intron primer pairs to conduct mutation analysis of the entire coding region of hSmad5 (Table 3) . No homozygous deletions were detected in 40 primary gastric cancers from Chinese patients surgically resected at the School of Oncology, Beijing Medical University and 51 human cancer cell lines that included tumors of the head and neck, retina, breast, lung, esophagus, stomach, liver, colon, pancreas, cervix, skin, ovary, and blood (Table 1) (Gemma et al., 1996; Vincent et al., 1997) by PCR ampli®cation of each exon ( Figure 5 ). This set of cell lines included 20 that were reported to be completely or substantially resistant to growth inhibition by TGF-b 1 (Table 1) (Fynan and Reiss, 1993; Vincent et al., 1997) . We did not ®nd aberrant bands in SSCP analysis of the same PCR products. PCR ± SSCP were performed as previously described (Gemma et al., 1996) . 32 P-labeled PCR products from ampli®cation of exons 2, 3 and 7 were digested with HpaII, BfaI, and NlaIV, respectively, to generate smaller fragments for more sensitive SSCP analysis.
We report the ®rst full-length cDNA of hSmad5 including the complete 5' region plus the promoter sequence with structural and functional analysis. In addition, we found an alternatively spliced mRNA transcript which lacks exon 2. The hSmad5 cDNA sequence was ®rst reported by Riggins and coworkers who described this family of proteins and deposited the sequence in GenBank (accession No. U59914); they recently published a complete protein sequence plus mutation analysis of common human cancers (Riggins et al., 1997) . We added more than 279 nucleotides to the 5' region including exons 1, 2, and part of 3, and con®rmed the existing sequences which are identical except for several amino acid dierences. We con®rmed Figure 4 Sequence and CpG analysis of the hSmad5 promoter. In order to clone the promoter region of hSmad5, YAC clone, 745f8, was digested with EcoRI and SstI. Southern blot hybridization using a radiolabeled 40 base oligonucleotide probe near the 5' end of the hSmad5 cDNA (5' ± 3': CCCGACGC-CGTTGCGCTTCTCCTCGCTGCAA CTTTATTAG) showed a 6 kb band. These DNA fragments were subcloned into pCRScript TM SK (7) phagemid (Stratagene, La Jolla, CA). The resulting genomic sublibrary was screened using the 40 base oligonucleotide probe. The % G+C and CpG content were analysed in a sliding window of 100 bp across the region of interest as described previously (Gardiner-Garden and Frommer, 1987) . The window for observed/expected (Obs/Exp) ratio for CpG was shifted in increments of 10 bp, giving a moving average across the DNA. (a) nucleotide sequence of the hSmad5 promoter (underlined sequence is exon 1.) (b) C+G content of hSmad5 promoter. (c) Obs/Exp ratio for CpG. (Exon 1 starts from 1239 bp We identi®ed and characterized the promoter region which has some unusual structural features. For example, this promoter has a CpG island which starts 200 nucleotides upstream from the transcription starting site and extends to exon 1. Although most 5' CpG islands linked to protein ± coding genes extend past the translation starting site, in this case, the translation initiation site lies within exon 3 which is downstream of the CpG island. Although atypical, similar architectures occur in chicken cytochrome C, murine ribosomal protein L32, and human proopiomelanocortin (Gardiner-Garden and Frommer, 1987) . Although most genes with 5' CpG islands within the promoter contain at least one G/C box, hSmad5 lacks both G/C and TATA boxes as well as CAAT sequences. None of these features are obligatory since the rat enkephalin and human somatostatin I genes do not contain G/C boxes within the promoter region. A 10-base pair sequence (CCCGCCTCCT) in the p21 waf1/cip1 promoter was reported to be essential for activation by TGF-b 1 (Datto et al., 1995) , but the sequence obtained in this study does not contain this TGF-b 1 responsive element.
hSmad5 has strong homology with the other Mad related proteins, hSmad1-4, in the amino-and carboxyterminal domains, which are separated by a prolinerich sequence. The hSmad protein with the greatest homology to hSmad5 is hSmad1 which has been suggested as a mediater of BMP-2 and BMP-4 (Liu et al., 1996) signaling. TGF-b 1 was reported to induce phosphorylation of both hSmad5 and hSmad1 proteins (Yingling et al., 1996) ; this result may re¯ect either the complexity of signaling or cross-reactivity of antibodies used to recognize hSmad1 and hSmad5 proteins. hSmad5 produces two dierent mRNAs by alternative splicing; the functional dierences of these two transcripts are not known.
We analysed hSmad5 to test the hypothesis that mutational inactivation of this gene is a mechanism of TGFb 1 resistance. TGF-b 1 inhibits proliferation of epithelial cells and resistance to TGF-b 1 is a common feature of human cancers Lechner et al., 1983) . For example, mutational inactivation of the TGF-b type II receptor interrupts TGF-b 1 regulation at the cell membrane, and these mutations occur commonly in colon (Vincent et al., 1997; Parsons et al., 1995; Takenoshita et al., 1997) and gastric cancers (Park et al., 1994) with microsatellite instability. In addition to type II receptor mutations, inactivation of downstream signal transduction proteins is a logical mechanism to mediate TGF-b 1 resistance, and there is some evidence to support this hypothesis. For example, the hSmad4 gene is mutated in pancreatic tumors (Hahn et al., 1996) , and hSmad2 is altered in some colon cancers (Riggins et al., 1996; Eppert et al., 1996) . We found no evidence for hSmad5 genomic alteration in 40 primary gastric cancers; we analysed gastric cancers because they have common allelic deletion of chromosome 5q31, the location of hSmad5. Likewise, there were no somatic mutations in a series of 51 human tumor cell lines which included 20 cell lines known to be resistant to TGF-b 1 . Although we recently reported mutations in the TGF-b type II receptor in three colon cell lines with microsatellite instability (Vincent et al., 1997) , the mechanisms for TGF-b 1 resistance remain unknown for most human cell lines. Our results are consistent with the ®ndings of Riggins and coworkers (Riggins et al., 1997) who found no mutations in 167 early-passage human cell lines representing tumors of the colon, breast, brain, lung, pancreas, head and neck and others. These two data sets indicate that hSmad5 mutations are infrequent among the common human cancers.
In summary, we completed the structural analysis of the hSmad5 gene and surveyed primary human cancers and cell lines for mutations. Although hSmad5 is a biologically plausible target for mutational inactivation of the TGF-b 1 signaling pathway, we found no alterations in this initial survey. Controlled expression of the hSmad5 gene and functional analysis of its protein product may better de®ne its role in the TGFb 1 superfamily pathways.
Abbreviations hSmad5, human hSmad5; TGF-b 1 , Transforming Growth Factor-b 1 ; bp, base pair; PCR ± SSCP, polymerase chain reaction ± single strand conformation polymorphism.
